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Objectives. Amongst nondiabetic individuals, a high
serum homocysteine concentration is an independ-
ent but relatively weak risk factor for coronary
events. However, it is not known whether homo-
cysteine increases risk of coronary events in type 2
diabetes. Therefore, we examined the combined ef-
fect of homocysteine and type 2 diabetes on risk of
fatal and nonfatal coronary events.
Subjects. We assessed the 10-year risk of coronary
events associated with homocysteine amongst dia-
betic (n ¼ 140) and nondiabetic (n ¼ 361) individ-
uals.
Design. We did this in the Hoorn Study, a popula-
tion-based study of glucose tolerance and related
complications in Caucasian men and women aged
50–75 years.
Results. The incidence rate for coronary events was
2.63 (29 of 140) per 100 person-years amongst
diabetic and 1.29 (42 of 361) amongst nondiabetic
individuals. Amongst diabetic individuals, risk of
coronary events increased 28% for each 5-lmol L)1
increment of homocysteine (hazard ratio, 1.28; 95%
CI, 1.02–1.58). This risk was independent of age,
sex, hypertension, total cholesterol, HDL-cholesterol,
cigarette smoking, body mass index and glomerular
filtration rate. In nondiabetic participants, homocy-
steine was not associated with an increased risk of
coronary events (hazard ratio for each 5-lmol L)1
increment of homocysteine, 0.86; 0.52–1.41).
Conclusions. These data suggest that homocysteine
is significantly associated with coronary events in
individuals with type 2 diabetes, independent of tra-
ditional cardiovascular risk factors. Investigation of
the effect of treatment with vitamin B on prognosis of
individuals with type 2 diabetes is warranted.
Keywords: cardiovascular disease, coronary artery
disease, diabetes, folic acid, homocysteine, preven-
tion.
Introduction
Amongst nondiabetic individuals, hyperhomocy-
steinaemia is an independent risk factor for cardio-
vascular and all-cause mortality. In addition, it
increases risk of fatal and nonfatal coronary events
[1, 2], although the association with coronary
events is relatively weak [3].
Type 2 diabetes causes excess cardiovascular
morbidity and mortality, predominantly as a result
of coronary events [4]. The increased cardiovascular
risk in type 2 diabetes is not fully explained by
conventional cardiovascular risk factors. Alternative
risk factors, such as homocysteine, may partly
explain this increased risk. Prospective data con-
cerning this issue are scarce. In previous studies,
homocysteine was found to be a strong risk factor
for all-cause and cardiovascular mortality in type 2
diabetes [5–7]. However, there are no data on the
(disease-specific) association of homocysteine with
coronary events amongst individuals with type 2
diabetes. If homocysteine concentration is associated
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with coronary events in type 2 diabetes, lowering
homocysteine concentration may be an additional
target for the prevention of fatal and nonfatal
coronary events amongst individuals with type 2
diabetes.
In view of these considerations, the present study
assessed the combined effect of hyperhomocystein-
aemia and type 2 diabetes on the risk of coronary
events during 10 years of follow-up. We addressed
these issues in the Hoorn Study, which was specif-
ically designed to examine type 2 diabetes as a
cardiovascular risk factor [8].
Materials and methods
Study population
The Hoorn Study is a population-based cohort study
on glucose intolerance and other cardiovascular risk
factors in a 50- to 75-year-old-general Caucasian
population, which started in 1989. The study
population has been described in detail before [8].
Briefly, 2484 individuals (71% of those invited)
participated. All participants, except previously
diagnosed as diabetic individuals treated with oral
glucose-lowering agents or insulin, underwent an
oral glucose tolerance test (OGTT) according to
the WHO guidelines [9]. For reasons of effi-
ciency, participants with a 2-h postload glucose
‡7.5 mmol L)1, all participants with type 2 diabetes
and a random sample of participants with a 2-h
postload glucose <7.5 mmol L)1, stratified by age
and sex, were invited within 4 weeks for a second
visit to investigate glucose-intolerance-related com-
plications [709 invited, of whom 631 (89%) parti-
cipated]. These participants underwent a second
OGTT (except those who already used blood-glucose-
lowering agents; n ¼ 67). Participants in the pre-
sent study population thus represented a stratified
random sample of all individuals with normal or
impaired glucose tolerance or type 2 diabetes in the
initial cohort [8].
The Ethical Review Committee of the VU Univer-
sity Medical Center approved the Hoorn Study.
Informed consent was obtained from all participants.
Laboratory and clinical assessments
After an overnight fast, blood was drawn from
an antecubital vein. We measured serum total
homocysteine, glucose, HbA1c, creatinine, total cho-
lesterol, HDL-cholesterol and triglycerides. Concen-
trations of serum total (free plus protein-bound)
homocysteine were assessed in frozen ()20 C)
Ethylene diaminetetraacetic acid (EDTA) serum by
using high-performance liquid chromatography with
fluorescence detection [10]. The intra- and inter-
assay coefficients were 2.1 and 5.1%, respectively.
Serum total cholesterol, HDL-cholesterol and trigly-
ceride levels were measured by enzymatic techniques
(Boehringer-Mannheim, Mannheim, Germany) and
serum creatinine by means of modified Jaffe´ method
[5]. We estimated the glomerular filtration rate by the
method of Levey et al. which is thought to be more
accurate than the Cockcroft–Gault formula [11–13].
Blood pressure was measured as the mean of four
measurements performed on two different occasions,
by means of a random-zero sphygmomanometer
under standardized conditions. Hypertension was
defined according to the criteria of the World Health
Organization (at time of data collection) as follows: a
systolic blood pressure of ‡160 mmHg and/or a dia-
stolic blood pressure of ‡95 mmHg, and/or the use of
antihypertensive medication [14]. Use of more recent
criteria, i.e. systolic blood pressure ‡140 mmHg and/
or diastolic blood pressure of ‡90 mmHg [15], for
hypertension, did not influence the results (data not
shown). Participants were classified as current cigar-
ette smokers, nonsmokers or former smokers. We
calculated body mass index (BMI) and waist-to-hip
ratio as previously described [8]. Finally, we obtained
an ankle–brachial blood pressure index and a resting
electrocardiogram. Participants were classified as
having cardiovascular disease when they had a
positive history of myocardial infarction and/or had
an electrocardiogram with a Minnesota code 1.1–
1.3, 4.1–4.3, 5.1–5.3 or 7.1 and/or had undergone
coronary bypass surgery or angioplasty, and/or had
an ankle–brachial blood pressure index of less than
0.9 in either leg and/or had undergone a peripheral
arterial bypass or amputation.
Follow-up
The population register of the city of Hoorn provided
the vital status of participants until 1 January,
2000. Causes of death were extracted from the
medical records of the general practitioner and the
local hospital. Information about nonfatal coronary
events was obtained by reviewing medical records of
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the hospital of Hoorn. Of 24 individuals who moved
out of town, we obtained information on (non) fatal
events from the new local municipalities, general
practitioner and hospital. A total of 130 individuals
of 631 candidate participants could not be included
because they refused permission for their records to
be reviewed (amongst these 25 who moved). We
coded causes of death and nonfatal events, as
diagnosed by the doctor and as written in the
medical records, according to the International
Classification of Diseases, Injuries, and causes of
Death, ninth revision (ICD-9) [16]. If a participant
died within 28 days after a nonfatal coronary event,
the event was classified as fatal. Fatal and nonfatal
coronary events were defined as ICD-9 codes 410–
414 (‘ischaemic heart diseases: myocardial infarc-
tion, angina pectoris and other manifestations of
ischaemic heart disease’).
Statistical analyses
For all analyses we used SPSS 10.1 for Windows.
Data are presented as mean (±standard deviation) or
median (interquartile range). Differences between
groups in continuous variables were tested with
Student’s t-test; in case of a skewed distribution with
the Mann–Whitney test; and in case of percentages
with the chi-square test. P-values were based on
two-sided tests and were considered statistically
significant if <0.05. Linear regression analysis was
used to assess baseline associations between homo-
cysteine concentration and cardiovascular risk
factors.
We used Cox regression to estimate hazard ratios
of coronary events as a function of serum homocy-
steine concentration. Analyses were stratified for the
presence of diabetes [5, 17]. In addition, we used
Cox regression to estimate the effects of cardiovas-
cular risk factors on coronary events. Coronary
events were defined as the first fatal or nonfatal
coronary event during follow-up. Individuals with
missing values for fatal or nonfatal events were
omitted from the analyses. We calculated hazard
ratios for homocysteine as a continuous variable,
expressed per 5 lmol L)1 increment of homocyste-
ine, and as a categorical variable (to allow for a
nonlinear dose–response relation) [5, 18]. In the
analyses with homocysteine as a categorical vari-
able, we computed hazard ratios for homocysteine
divided in four categories (£9, 9.1–14.0, 14.1–19.0
and >19.0 lmol L)1, respectively) [5, 18]. To test
for trend, the four categories were added to the
analyses as an ordinal variable.
Serum homocysteine concentrations were meas-
ured only at baseline. As a result of long-term
within-person variability, a single measurement will
lead to underestimation of the true association
between the long-term average homocysteine con-
centration and disease rates [19]. Therefore, we
adjusted hazard ratios for this so-called ‘regression
dilution bias’ using a regression equation calculated
by Clarke et al. on the basis of regression dilution
ratios (RDR) of four prospective studies with repea-
ted homocysteine measurements. The RDR was
calculated as 0.89–0.03T. T stands for years
between measurements; thus after 9.8 years of
follow-up in the present study, the RDR would be
0.60 [20]. We also calculated the RDR in a sample
(n ¼ 72) of nondiabetic individuals of the Hoorn
Study in whom homocysteine was remeasured
9.5 years after the initial examination. We found
an RDR of 0.70, which is of a similar magnitude as
the value calculated above. In the present analyses,
we chose to use the RDR of Clarke et al. because this
was based on a much greater number of individuals
[20], and to set T at 4.9 (i.e. halfway through
the follow-up period [19]; thus RDR ¼ 0.89 )
0.03 · 4.9 ¼ 0.74). Hazard ratios therefore repre-
sent risks associated with 4.9-year average homo-
cysteine concentration, which is probably more
useful than risks associated with homocysteine
concentration at baseline. Hazard ratios displayed
in Table 2 are thus corrected for regression dilution
bias. (Uncorrected hazard ratios can be easily back-
calculated by taking the corrected hazard ratio to
the power of 0.74; for example, when the corrected
hazard ratio is 1.25, the uncorrected hazard ratio is
1.250.74 ¼ 1.18) P-values are not influenced by this
correction.
In the first regression model, we calculated hazard
ratios adjusted for the stratification variables age
and sex. In the second model, we additionally
adjusted for other major classical risk factors for
cardiovascular disease, namely, total cholesterol,
HDL-cholesterol, hypertension, cigarette smoking
and BMI [21]. Potential confounders measured on
a continuous scale were used as such in the
regression analyses, except for HDL-cholesterol
and BMI, because their association with coronary
events was nonlinear. Therefore, HDL-cholesterol
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concentration was defined as low if <0.9 mmol L)1
[22], and BMI was defined as high if >27 kg m)2 in
men and >26 kg m)2 in women [23]. We computed
product terms (such as diabetes · homocysteine) to
assess whether homocysteine interacted with any
cardiovascular risk factor or with time.
Results
Characteristics of the participants
At baseline, the cohort consisted of 174 diabetic and
457 nondiabetic individuals. Thirty-four diabetic
and 96 nondiabetic individuals had missing values
for nonfatal events and were excluded. Persons who
were excluded did not differ from persons who were
not excluded with regard to baseline characteristics
(data not shown). Table 1 shows baseline charac-
teristics and hazard ratios of coronary events asso-
ciated with cardiovascular risk factors. Of all type 2
diabetic individuals, 73 (52.1%) were newly detec-
ted and 67 (47.9%) were known to have diabetes.
The median duration of diabetes amongst individu-
als with previously diagnosed diabetes was 6.2
(interquartile range: 2.6–11.5) years. After up to
10 years of follow-up (median, 9.8; range, 0.5–
11.2 years), 50 amongst 140 diabetic individuals
had died (three died as a result of coronary events)
versus 57 amongst 361 nondiabetic individuals (six
died as result of coronary events). During follow-up
29 amongst 140 diabetic individuals had one or more
nonfatal coronary events as opposed to 42 amongst
361 nondiabetic individuals. Of the excluded 130
individuals, 12 persons died due to an unknown
cause. Table 2 displays baseline associations between
homocysteine and cardiovascular risk factors.
Coronary events
The incidence rate of coronary events per 100
person-years was 2.63 (31 cases amongst 140
individuals during 1177 person-years) amongst
diabetic and 1.29 (47 cases amongst 361 individ-
uals during 3631 person-years) amongst nondia-
betic individuals (Table 3).
Table 3 shows that, amongst diabetic individuals,
homocysteine was significantly associated with 10-
year risk of coronary events. After adjustment for
other cardiovascular risk factors, the risk of coron-
ary events rose with 1.28 (95% CI, 1.02–1.58) for
each 5 lmol L)1 increment of serum homocysteine.
Per category increment of homocysteine, the hazard
ratio was 1.55 (CI, 0.84–2.86); after adjustment for
confounders, it was 1.75 (CI, 0.92–3.36) (Fig. 1).
Table 1 Baseline characteristics and hazard ratios of coronary events associated with cardiovascular risk factors
Nondiabetic
individuals
(n ¼ 361)
Diabetic
individuals
(n ¼ 140) P-valuea
Difference in
risk factor
Coronary events
RR (95% CI)b
Male gender (%) 51.0 47.1 0.59 Yes versus no 1.25 (0.79–1.95)
Age (years) 63.4 (7.1) 65.7 (6.8) 0.001 Per year increase 1.04 (1.01–1.08)
Total homocysteine (lmol L)1)c 11.3 (9.4–14.1) 11.2 (9.1–13.6) 0.41 Per lmol L)1 increase 1.02 (0.99–1.05)
HbA1c (%) 5.4 (0.5) 7.2 (1.9) <0.001 Per 1% of haemoglobin 1.04 (0.87–1.24)
Body mass index (kg m)2) 26.6 (3.5) 28.6 (4.5) <0.001 High versus low 0.67 (0.42–1.06)
Smoker (no/yes/former) (%) 36.3/26.0/37.7 42.0/22.5/35.5 0.48 Yes versus no
Former versus no
2.15 (1.16–4.01)
1.72 (0.94–3.14)
Systolic blood pressure (mmHg) 137.0 (19.3) 144.3 (19.0) <0.001 Per mmHg increase 1.01 (1.0–1.02)
Diastolic blood pressure (mmHg) 82.3 (10.0) 83.0 (10.4) 0.49 Per mmHg increase 1.00 (0.98–1.02)
Hypertension (%) 32.4 54.3 <0.001 Yes versus no 2.09 (1.32–3.32)
Total cholesterol (mmol L)1) 6.7 (1.1) 6.4 (1.3) 0.013 Per mmol L)1 increase 1.22 (1.02–4.47)
HDL-cholesterol (mmol L)1) 1.3 (0.4) 1.1 (0.3) <0.001 High versus low 0.59 (0.27–1.27)
Triglycerides (mmol L)1)c 1.5 (1.1–2.1) 1.9 (1.3–2.9) <0.001 Per 10% increase 1.88 (1.22–2.88)
Glomerular filtration rate (mL min)1)d 67.8 (11.3) 68.2 (14.3) 0.80 Per mL min)1 increase 0.99 (0.97–1.01)
Prior cardiovascular disease (%) 18.8 33.6 <0.001 Yes versus no 3.17 (1.98–5.07)
Data are presented as mean (SD), percentage of the total or median (interquartile range); adiabetic versus nondiabetic individuals; badjusted
for age, sex and diabetes, except when this was the variable under consideration; cmedian (interquartile range); destimated by the method of
Levey et al. [11]; n ¼ number; HDL cholesterol, high-density-lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval; because of a
non-linear association with coronary events HDL-cholesterol was entered above versus below 0.9 mmol L)1, body-mass index above versus
below 27 kg m)2 for men and above versus below 26 kg m)2 for women and triglycerides per 10% increase.
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Amongst nondiabetic individuals, homocysteine
was not significantly related to risk of coronary
events (Table 3). Hazard ratios per 5 lmol L)1
increment of serum homocysteine thus differed
between individuals with and without diabetes
(hazard ratios, 1.28; CI, 1.02–1.58 vs. 0.86; CI,
0.52–1.41, respectively). However, the test for
interaction was nonsignificant (P-value of the prod-
uct term diabetes · homocysteine was 0.29 and for
diabetes · homocysteine in four categories, 0.22).
In addition, we did not observe significant interac-
tions between serum homocysteine and cardiovas-
cular risk factors other than diabetes. We also did
not find a significant time-to-event dependency for
the association between homocysteine and coronary
events in diabetic or in nondiabetic individuals.
Therefore, the proportional hazards assumption is
satisfied.
Additional analyses
After additional adjustment for prior cardiovascular
disease at baseline [13], the association between
homocysteine and coronary events amongst diabetic
individuals became borderline significant (HR, 1.22;
95% CI, 0.97–1.54). However, adjustment for this
variable may amount to overadjustment, as card-
iovascular disease most likely is an intermediate fac-
tor in the causal pathway linking homocysteine
to coronary events [24]. Individuals with prior
cardiovascular disease had a higher homocyste-
ine concentration than individuals without prior
Table 2 Homocysteine concentra-
tions: baseline associations with
cardiovascular risk factors
ba SE(b)a P-value
Gender (Male versus female) 0.12 0.029 <0.001
Age (per 1 year increase) 0.011 0.002 <0.001
Diabetes (Yes versus no) )0.049 0.032 0.13
HbA1c (Per 1% of haemoglobin) 0.0038 0.013 0.77
Body mass index (per 1 kg m)2 increase) 0.0019 0.004 0.61
Smoker
Yes versus no 0.083 0.037 0.026
Former versus no 0.0089 0.017 0.60
Systolic blood pressure (Per 1 mmHg increase) 0.0012 0.001 0.092
Diastolic blood pressure (Per 1 mmHg increase) 0.0011 0.001 0.39
Hypertension (Yes versus no) 0.041 0.028 0.14
Total cholesterol (Per 1 mmol L)1 increase) 0.011 0.011 0.13
HDL cholesterol (Per 1 mmol L)1 increase) )0.054 0.039 0.17
Triglycerides (Per 1 mmol L)1 increase) 0.016 0.011 0.13
Glomerular filtration rate (Per 1 mL min)1 increase) )0.01 0.001 <0.001
Prior cardiovascular disease (Yes versus no) 0.065 0.031 0.039
aRegression coefficient (b), standard error [SE(b)] and P-value obtained by linear regression analyses
with homocysteine concentration (log-transformed because of a better fit of the regression model) as
dependent and risk factors as independent variable, all adjusted for age, sex and diabetes (unless this
was the variable under consideration); estimated by the method of Levey et al. [11].
Table 3 Hazard ratios (95% con-
fidence intervals) for coronary
events associated with homocyste-
ine during 10 years of follow-up Individuals
Coronary events
HRa HRb
Nondiabetic individuals
Total homocysteine (Per category increment) 0.84 (0.49–1.44) 0.76 (0.44–1.31)
Total homocysteine (Per 5 lmol L)1 increment) 0.91 (0.57–1.44) 0.86 (0.52–1.41)
Diabetic individuals
Total homocysteine (Per category increment) 1.55 (0.84–2.86) 1.75 (0.92–3.36)
Total homocysteine (Per 5 lmol L)1 increment) 1.25 (1.02–1.53) 1.28 (1.02–1.58)
HR, hazard ratio; aadjusted for age and sex; badjusted for age, sex, hypertension, total cholesterol,
HDL-cholesterol, body mass index and smoking.
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cardiovascular disease: 12.2 (9.7–15.6) lmol L)1
vs. 11.1 (9.2–13.8) lmol L)1; P-value, 0.03.
Secondly, additional adjustment for diabetes
duration, glomerular filtration rate or waist-to-hip
ratio did not materially influence any of the
associations (data not shown). Finally, we investi-
gated whether individuals with a normal and an
impaired glucose tolerance could reasonably be
considered as one group. In stratified analyses, we
found that hazard rates were similar for individuals
with a normal and an impaired glucose tolerance
(data not shown).
Discussion
The novel finding in this study is that homocysteine is
a risk factor for coronary events in type 2 diabetes. We
observed, in a population-based study with a 10-year
follow-up period, a significant dose–response relation
between homocysteine concentration and risk of
coronary events. For each 5 lmol L)1 increment of
serum homocysteine, the risk of coronary events rose
by 28% (95% CI, 2–58).
Total homocysteine was a significant risk factor
for coronary events in individuals with, but not
without, type 2 diabetes. This is compatible with a
recent meta-analysis, which has suggested that
homocysteine is a relatively weak risk factor for
coronary events [3]. In addition, studies suggest that
homocysteine is most clearly associated with
cardiovascular disease in high-risk populations
[25–27]. Therefore, an association between homo-
cysteine and coronary events may be clearest
amongst individuals with type 2 diabetes, because
they are at high risk of coronary heart disease. The
biological mechanism for the interaction, if any,
between homocysteine and type 2 diabetes is not
clear. Hyperhomocysteinaemia may enhance ather-
othrombotic pathways through accelerating direct
cytotoxic effects of glucose and through increasing
glucose-induced oxidative stress on endothelial cells
[5, 28]. Support for the latter hypothesis was
recently provided by Shukla et al. who demonstrated
that concentrations of homocysteine which had no
effect on aortae from normal rabbits markedly
reduced bioavailability of nitric oxide in aortae from
diabetic rabbits, an effect that was fully reversed
with superoxide dismutase [29].
In type 2 diabetes, homocysteine may be a risk
factor not only for coronary events, but also for
cardiovascular mortality [5], retinopathy [30] and
microalbuminuria [31, 32]. In contrast, the associ-
ation of homocysteine with micro- and macro-angi-
opathy in type 1 diabetes has not been extensively
investigated, and this issue requires further study
[33].
Long-term within-person fluctuations of homocy-
steine may lead to a systematic underestimation of
the magnitude of the association between homocy-
steine and coronary events, especially after long
follow-up periods, which is referred to as ‘regression
dilution bias’ [19, 20]. The same phenomenon has
been demonstrated for blood pressure and serum
cholesterol [19, 34]. As suggested by Clarke et al. we
adjusted hazard ratios for regression dilution to
obtain a better estimate of the true strength of the
1 1
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Fig. 1 Adjusted hazard ratios for
coronary events amongst individu-
als with type 2 diabetes per cate-
gory increment of homocysteine
(£9, 9.1–14.0, 14.1–19.0 and
>19.0 lmol L)1, respectively).
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associations between average long-term homocyste-
ine concentrations and disease risk [20]. The RDR
calculated with data from a small sample of the
Hoorn Study was comparable with the RDR of
Clarke et al. [20] We decided to use the latter RDR,
because this was calculated on the basis of four large
studies.
Primary prevention is important in individuals
with type 2 diabetes, especially because 50% of
patients with type 2 diabetes may die within the first
year after a first cardiac event [35]. As we observed
that homocysteine was associated-coronary events
in individuals with diabetes, lowering concentra-
tions of homocysteine may be an attractive addi-
tional target for primary and secondary prevention
in type 2 diabetes. Homocysteine concentrations can
easily be lowered by daily supplementation with folic
acid and possibly vitamin B12 [36]. However, results
of large trials have to be awaited to know whether
lowering homocysteine concentrations with vitamin
B does indeed decrease risk of coronary events [37].
This study had several limitations. The population
consisted of individuals aged 50–75 years, all
belonging to caucasian population. Therefore, we
do not know whether our findings can be general-
ized to younger or older individuals, or to other
ethnic groups. Secondly, the associations we found
between homocysteine and coronary events might
have been affected by nondifferential misclassifica-
tion, because events had to be classified according to
specific causes. This generally results in an under-
estimation of the true effect [24]. Thirdly, results
may be affected by information bias, because doctors
may be more alert in detecting coronary events in
diabetic patients, as they are already at a higher risk
for coronary events than people without diabetes.
However, this is the case in most follow-up studies.
Our study lacked power to address associations
between homocysteine and risk of other or more
specific nonfatal cardiovascular endpoints, such as
stroke and myocardial infarction. Finally, our data
had insufficient power to firmly establish (or exclude)
a threshold effect, and to assess whether the strength
of the association of homocysteine concentrations
with fatal coronary events differed significantly from
that with nonfatal coronary events. These issues need
to be investigated in a larger study.
In conclusion, we observed that total homocysteine
concentration was associated with risk of coronary
events amongst individuals with type 2 diabetes. In
addition, other studies found that, amongst individ-
uals with type 2 diabetes, homocysteine was associ-
ated with retinopathy [30] and microalbuminuria
[31, 38]. Therefore, investigation of the effect of
treatment with vitamin B on prognosis of individuals
with type 2 diabetes is warranted.
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